Moderate

Eosinophilia work-up

eosinophilia w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Raised eosinophils range from mild reactive responses (allergy, parasites, drugs) to marked eosinophilia with organ damage from clonal or hypereosinophilic syndromes. Degree of elevation and end-organ involvement drive urgency.

Red flags

  • Cardiac involvement (eosinophilic myocarditis, troponin rise)
  • Neurological deficits
  • Respiratory failure
  • Very high eosinophil count with organ dysfunction
  • Thromboembolism

Assessment

Differential diagnosis

  • Reactive (allergy, asthma, drug reaction, parasites)
  • Hypereosinophilic syndrome
  • Clonal/myeloid eosinophilia (PDGFRA/B, FGFR1 rearrangements)
  • Lymphoma/other malignancy
  • Eosinophilic granulomatosis with polyangiitis
  • Adrenal insufficiency

Investigations

  • FBC with absolute eosinophil count and film
  • Review drug history and travel/parasite exposure
  • Stool ova/parasites, strongyloides serology, IgE
  • Tryptase, B12 and molecular testing (FIP1L1-PDGFRA)
  • End-organ assessment: troponin/ECG/echo, chest imaging, LFTs
  • Bone marrow and cytogenetics if clonal disease suspected

Management

  • Grade the eosinophilia and determine chronicity
  • Assess for end-organ damage (cardiac, pulmonary, neurological, skin, GI)
  • Review medications and stop likely culprit drugs
  • Screen for parasitic infection, especially before giving steroids (strongyloides hyperinfection risk)
  • Investigate allergic and reactive causes
  • Test for clonal myeloid eosinophilia (FIP1L1-PDGFRA and related rearrangements) when persistent/unexplained
  • Exclude secondary malignancy and vasculitis
  • For marked eosinophilia with organ involvement, treat urgently with corticosteroids after excluding strongyloides
  • Treat PDGFR-rearranged disease with imatinib (highly responsive)
  • Manage hypereosinophilic syndrome with steroids and steroid-sparing agents; monitor organs

Drugs & doses

Prednisolone 0.5-1 mg/kg PO daily for symptomatic hypereosinophilic syndrome (after excluding strongyloides)
Imatinib 100-400 mg PO daily for PDGFRA/B-rearranged eosinophilia
Ivermectin to cover strongyloides before steroids where risk exists
Mepolizumab for selected eosinophilic conditions

Disposition

Outpatient work-up for mild reactive cases; urgent admission and specialist care for organ involvement.

Complications & pitfalls

  • Endomyocardial fibrosis and heart failure
  • Thromboembolism
  • Pulmonary and neurological damage
  • Strongyloides hyperinfection if steroids given without cover
  • Progression of clonal disease

Exam pearls

  • Always consider and cover strongyloides before giving corticosteroids
  • PDGFRA-rearranged eosinophilia responds dramatically to imatinib
  • Cardiac involvement drives mortality - check troponin and echo in marked eosinophilia
  • Drugs are a very common reversible cause
  • Persistent unexplained eosinophilia warrants molecular testing

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.